Stay up to date on the latest oncology and nursing conferences.
Adding Pembrolizumab to Lenvatinib Shows ‘Encouraging’ DOR in Advanced HCC
January 20th 2024Patients with advanced hepatocellular carcinoma treated with frontline pembrolizumab plus lenvatinib showed a 3-year or more response among 35% of responders, although additional efficacy results from the trial are consistent with previous findings from the phase 3 LEAP-002 trial.
Patients With ESCC Derive Survival Benefit With Tiragolumab Plus Atezolizumab and Chemotherapy
January 20th 2024Patients with esophageal squamous cell carcinoma obtained significant survival improvements when treated with tiragolumab plus atezolizumab and chemotherapy compared with chemotherapy alone.
Adding Nivolumab to Chemo Increases OS, PFS in Previously Untreated Advanced GI Cancers
January 19th 2024Overall survival and progression-free survival improves with nivolumab plus chemotherapy compared with chemotherapy alone in the overall population and in patients with a PD-L1 CPS of 5 or greater.
HER2+ Breast Cancer May Respond to Neoadjuvant HER2 Blockade Plus Polychemotherapy
January 16th 2024Treatment with pegylated liposomal doxorubicin and cyclophosphamide in the neoadjuvant setting, followed by a taxane, in addition to trastuzumab and pertuzumab, resulted in antitumor activity in patients with HER2-positive breast cancer.
Pirtobrutinib Generates Durable Responses in CLL/SLL After BTKi Therapy
December 11th 2023The use of pirtobrutinib following covalent Bruton tyrosine kinase inhibitor therapy may be an important sequencing approach in chronic lymphocytic leukemia/small lymphocytic lymphoma, according to recent research.
Neoadjuvant/Adjuvant Pembrolizumab Regimen Continues to Show EFS Benefit in High-Risk Early TNBC
December 10th 2023The 5-year event-free survival rate was 81.3% with neoadjuvant pembrolizumab/chemotherapy followed by adjuvant pembrolizumab, compared with 72.3% in those who received placebo/chemotherapy plus placebo.